About our Premium Reports
Our Premium Reports are specialized reports that are only available to active users with HealthTech Alpha Pro and HealthTech Alpha Enterprise accounts and are provided at no additional cost.
Asia Pac HealthTech ecosystem momentum continues unabated closing at the mid year point at US$2.5B invested, building on the back of a record breaking 2018. Early stage ventures deal activity shrinks yet further, whereas total Series B and C deal value continues to grow, grabbing 69% of total funding, raising questions regarding the sustainability of the deal flow of Growth stage investors.
Asia Pac HealthTech ecosystem momentum continues unabated closing at the mid year point at US$2.5B invested, building on the back of a record breaking 2018. Early stage ventures deal activity shrinks yet further, whereas total Series B and C deal value continues to grow, grabbing 69% of total funding, raising questions regarding the sustainability of the deal flow of Growth stage investors.
Our Premium Reports are specialized reports that are only available to active users with HealthTech Alpha Pro and HealthTech Alpha Enterprise accounts and are provided at no additional cost.
Galen Growth’s proprietary platform, HealthTech Alpha, provides the data source for this report. Corporate Business Development, Business Intelligence, and Digital Health Partnership teams worldwide prefer HealthTech Alpha, the world’s most-trusted Digital Health data, intel, and insights platform. Visit https://www.healthtechalpha.com to learn more about our data or https://www.galengrowth.com research for our reports.
Founded in 2016 by Digital Health experts, Galen Growth empowers global Fortune 500 companies, institutional investors, and promising Digital Health ventures to fast track their digital health strategy to create significant financial and social values. To find out more, visit https://www.galengrowth.com
